Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?

Arthritis and Rheumatism

Volumn 41, Issue 9, 1998, Pages 1564-1570

  Felson, David T ^a,d   Anderson, Jennifer J ^a   Lange, Mary L M ^b   Wells, George ^c   Lavalley, Michael P ^a  

^a BOSTON UNIVERSITY   (United States)

^b AMGEN INC   (United States)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURANOFIN; CYCLOSPORIN A; METHOTREXATE; PENICILLAMINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CLINICAL TRIAL; DISCRIMINANT ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; VALIDATION PROCESS;

EID: 0031680201     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199809)41:9<1564::AID-ART6>3.0.CO;2-M     Document Type: Article

References (18)

1. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
2. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
3. Pillemer SR, Fowler SE, Tilley BC, Alarcón GS, Heyse SP, Trentham DE, et al. Meaningful improvement criteria sets in a rheumatoid arthritis clinical trial. Arthritis Rheum 1997;40:419-25.
4. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
5. Van den Borne BEEM, Landewe RBM, Goei The HS, Breedveld FC, Dijkmans BAC. Low dose cyclosporine in early rheumatoid arthritis: effective and safe after two years of therapy when compared with chloroquine. Scand J Rheumatol 1996;25:307-16.
6. Paulus HE, Egger MJ, Ward JR, Williams HJ, and the Cooperative Systematic Studies of Rheumatic Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990;33:477-84.
7. O'Dell JR, Haire CE, Palmer W, Drymalski W, Wees S, Blakely K, et al. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1997;40:842-8.
8. Ferracciolo GF, Di Poi E, Damato R, Casatta L, De Vita S, Bartoli E. Analysis of remission and full responses in rheumatoid patients treated with combination therapy for three years [abstract]. Arthritis Rheum 1997;40 Suppl 9:S219.
9. Bombardier C, Tugwell P. A methodological framework to develop and select indices for clinical tasks: statistical and judgmental approaches. J Rheumatol 1982;9:753-7.
10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
11. Williams HJ, Willkens RF, Samuelson CO Jr. Alarcón GS, Guttadauria M, Yarboro C, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1985;28:721-30.
12. Williams HJ, Ward JR, Reading JC, Egger MJ, Grandone JT, Samuelson CO, et al. Low-dose D-penicillamine therapy in rheumatoid arthritis: a controlled double-blind clinical trial. Arthritis Rheum 1983;26:581-92.
13. Ward JR, Williams HJ, Egger MJ, Reading JC, Boyce E, AltzSmith M, et al. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1983;26:1303-15.
14. Weinblatt ME, Kaplan H, Germain BF, Merriman RC, Solomon SD, Wall B, et al. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis: a thirty-six-week, double-blind trial. Arthritis Rheum 1990;33:330-8.
15. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
16. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 1990;33:1449-61.
17. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/ toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: a metaanalysis of published clinical trials. Arthritis Rheum 1992;35:1117-25.
18. Cohen J. The arcsine transformation and the effect size index. In: Statistical power analysis for the behavioral science. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates; 1988. p. 180-5.